Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2003/005153external-prioritypatent/WO2003103714A1/en
Application filed by Pliva Lachema AsfiledCriticalPliva Lachema As
Publication of NO20045398LpublicationCriticalpatent/NO20045398L/en
Det er beskrevet et stabihsert farmasøytisk preparat omfattende et farmasøytisk aktivt stoff som er dårlig oppløselig i vann, et oppløseliggjørende middel med et lavt irmhold av både basiske og sure forbindelser og et polart organisk oppløsningsmiddel, spesielt et stabilisert injeksjonskonsentrat, fremgangsmåte for fremstilling av slike stabiliserte farmasøytiske preparater og anvendelsen av et oppløsehggj ørende middel med et lavt irmhold av både basiske og sure forbindelser for å stabilisere farmasøytiske preparater for farmasøytisk aktive stoffer.There is disclosed a stabilized pharmaceutical composition comprising a poorly water-soluble pharmaceutically active substance, a low solubilizer of both basic and acidic compounds, and a polar organic solvent, in particular a stabilized injection concentrate, process for preparing such stabilized pharmaceuticals. compositions and the use of a low-solubility agent of both basic and acidic compounds to stabilize pharmaceutical preparations for pharmaceutically active substances.
NO20045398A2002-06-102004-12-10
Stabilized pharmaceutical preparations based on polyoxyethylated castor oil and process for their preparation
NO20045398L
(en)
compound, use of a compound, pharmaceutical composition, pharmaceutical aerosol formulation, and method for treating a human or animal patient with an anti-inflammatory and / or allergic condition
New 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, processes for the preparation of the same, and pharmaceutical preparations containing the same
Use of melagatran or a pharmaceutically acceptable derivative or prodrug thereof, method of treating inflammation, and, pharmaceutical formulation for use in treating inflammation